Colloidal carriers: A rising tool for therapy of tuberculosis

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 29, Issue 4, 2012, Pages 299-353

  Gupta, Swati ^a,b   Kumar, Pankaj ^a   Gupta, Manish K ^a   Vyas, Suresh P ^c  

^a ISF COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c DR H S GOUR UNIVERSITY   (India)

Author keywords

Liposomes; Microparticles; Nanoparticles; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; COLLOIDAL CARRIER; COMPLEMENT RECEPTOR; CYCLOSERINE; DELAMANID; DRUG CARRIER; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SURFACTANT PROTEIN A; SUTEZOLID; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALOPECIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL GROWTH; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTHERAPY; CHOLESTASIS; CLINICAL FEATURE; CONVULSION; DEPRESSION; DISEASE COURSE; DISEASE TRANSMISSION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; EOSINOPHILIA; EXFOLIATIVE DERMATITIS; FLU LIKE SYNDROME; GAMMA DELTA T LYMPHOCYTE; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; GYNECOMASTIA; HEMOLYTIC ANEMIA; HOST RESISTANCE; HUMAN; HYPERURICEMIA; INJECTION SITE INDURATION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTOSIS; MALAISE; MEGALOBLASTIC ANEMIA; MINIMUM INHIBITORY CONCENTRATION; MONONUCLEOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NEPHRITIS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PAIN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PHYSICAL EXAMINATION; PRIMARY INFECTION; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; RETROBULBAR OPTIC NEUROPATHY; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; TUBERCULIN TEST; TUBERCULOSIS; VERTIGO; VISUAL DISORDER;

ANTITUBERCULAR AGENTS; COLLOIDS; DRUG CARRIERS; DRY POWDER INHALERS; HUMANS; MICROSPHERES; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; RISK FACTORS; TUBERCULOSIS;

EID: 84862610629     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v29.i4.20     Document Type: Article

References (172)

1. Somani RR, Gavarkar PS, Shirodkar PY, Bhanushali UV, Kadam VJ. Tropical diseases: an unsolved challenge. Int J PharmTech Res. 2010;2(3):1691-1698.
2. http://www.who.int/gho/tb/en/ (Accessed on Dec 23, 2011)
3. Nikki M, James D, William R, Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobac-terium tuberculosis. Trends Microb. 1998;6(3):107-112.
4. Amin Z. Clinical tuberculosis problems and management. Indones J Intern Med. 2006;38(2):109-116.
5. Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination. Core Curriculum on Tuberculosis: What the Clinician Should Know. 4th edition (2000). Updated August 2003. Available from http://www.cdc.gov/tb/topic/basics/default.htm.
6. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nature Med. 2000;6:1327-1329.
7. Kaufmann SHE. Is the development of a new tuberculosis vaccine possible? Nature Med. 2000;6:955-960.
8. Reddy JR, Kwang J, Lechtenberg KF, Khan NC, Reddy BP, Chengappa MM. An immunochro-matographic serological assay for the diagnosis of Mycobacterium tuberculosis. Comp Immunol Microbiol Inf Dis. 2002;25:21-27.
9. Riley R. Transmission and environmental control of tuberculosis. In Reichman L, Hershfeld E, editors. Tuberculosis. New York: Marcel Deckker; 1993.
10. Riley R. Airborne infection. Am. J. Med. 1974;57:466-475.
11. Murray J. Defense mechanisms. In Murray JF, editor. The normal lung: the basis for diagnosis and treatment of pulmonary disease. Philadelphia: Saunders WB; 1986. p. 313-338.
12. Horsburgh CR. Tuberculosis without tubercles. Tuberc. Lung Dis. 1996;77:197-198.
13. Bhatt CP, Bhatt AB, Shrestha B. Nepalese people's knowledge about tuberculosis. Saarc J Tuber Lung Dis HIV/AIDS. 2009;6(2):31-37.
14. CDC. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. 2000;49(RR-6):38-39.
15. Lee JH. The diagnosis of tuberculosis in the presence of silicosis. Can Med Assoc J. 1948;58(4):349-53.
16. http://emedicine.medscape.com/article/302027-overview.
17. http://www.merckmanuals.com/home/sec17/ch193/ch193a.html.
18. Griffth De, Kerr CM. Tuberculosis: disease of the past, disease of the present. J Perianesth Nurs. 1996;11(4):240-245.
19. Strachan DP, Powell KJ, Thaker A, Millard FJC, Maxwell JD. Vegetarian diet as a risk factor for tuberculosis in immigrant south London Asians. Thorax.1995;50:175-180.
20. Tso HW, Lau YL, Tam CM, Wong HS, Chiang KS. Associations between IL12B polymorphisms and tuberculosis in the Hong Kong Chinese population. J Infect Dis. 2004;190(5):913-919.
21. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002;347(23):1860-1866.
22. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989;46:183-219.
23. Taylor ME, Drickamer K. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor. J Biol Chem. 1993;268:399-404.
24. Nepomuceno RR, Henschen-Edman AH, Burgess WH, Tenner AJ. cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity. 1997;6:119-129.
25. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity. 1994;1:509-516.
26. Dunne DW, Resnick D, Greenberg J, Krieger M, Joiner KA. The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci USA. 1994;91:1863-1867.
27. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998;66:1277-81.
28. Gatfeld J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science. 2000;288:1647-1650.
29. Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and Mycobacterium tuberculosis infection. J Clin Virol. 2001;20:123-126.
30. Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. Cytokine activation leads to aci-dification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol. 1998;160:1290-1296.
31. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA. 2000;97:8841-8848.
32. Weber I, Fritz C, Ruttkowski S, Kreft A, Bange FC. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodefcient mice. Mol Microbiol. 2000;35:1017-1025.
33. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97:435-447.
34. Konstantinos A. Testing for tuberculosis. Australian Prescriber. 2010;33:12-18.
35. Kumar V, Abbas AK, Nelson F, Mitchell RN. Robbins basic pathology, 8th ed. Philadelphia: Saun-ders Elsevier; 2007:516-522.
36. Ormerod LP. Joint Tuberculosis Committee of the British Thoracic Society, control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. BMJ. 2000;55:887-901.
37. http://www.immunisation.nhs.uk/fles/mantouxtest.pdf.
38. Nahid P, Pai M, Hopewell P. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006;3(1):103-110.
39. McFadden JJ, Kunze Z, Seechum P. DNA probes for detection and identifcation. In: McFadden J, editor. Molecular biology of the mycobacteria. Surrey, UK: Surrey University Press. 1990; p. 139-172.
40. Kaminski DA, Hardy DS. Selective utilization of DNA probes for identifcation of Mycobacte-rium species on the basis of cord formation in primary BACTEC cultures. J Clin Microbiol. 1995;33:1548-1550.
41. Katoch VM, Sharma VD. Advances in the diagnosis of mycobacterial diseases. Ind J Med Microbiol. 1997;15:49-55.
42. Mathur JN. What is new in the diagonosis of tuberculosis. ICMR Bull. 2002;32(8).
43. Siddiqi SH, Libonati JP, Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 1981;13:908.
44. Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: a review. Tuber Lung Dis. 2000;80:131.
45. Albert H, Heydenrych A, Brookes R, Mole RJ, Harley B, Subotsky E, Henry R, Azevedo V. Performance of a rapid phage-based test, AST Plaque TB to diagnose pulmonary tuberculosis from sputum specimens in South Africa. Int J Tuber Lung Dis. 2002;6:529.
46. Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26(11):2401-2416.
47. Somani RR, Gavarkar PS, Shirodkar PY, Bhanushali UV, Kadam VJ. Tropical diseases: an unsolved challenge. Int J PharmTech Res. 2010;2(3):1691-1698.
48. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, Kumar S, Sarda P, Singh S. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Ind J Med Res. 2010;132:81-86.
49. Venable SJ. Drugs treating mycobacterial infections. In: Aschenbrenner DS, Venable SJ, editors. Drug therapy in nursing. Baltimore: Lippincott Williams & Wilkins; 2008. p. 828-841.
50. Smith PJ, van Dyk J, Fredericks A. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int J Lung Dis. 1999;3(11):S325-S328.
51. Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Goodman & Gilman's the pharmacological basis of therapeutics. Brunton L, Chabner B, Knollman B, editors. Columbus, OH: McGraw-Hill. 2006.
52. th ed. Columbus, OH: McGraw-Hill; 2009:1041-1050.
53. Hazre A, Laha B. Chemotherapy of osteoarticular tuberculosis. Ind J Pharmacol. 2005; 37(1):5-12.
54. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14:2000-2008.
55. Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med. 2006;12:179-185.
56. Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. Tohuku J Exp Med. 2010;221:97-106.
57. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Gros-set JH. Moxifoxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169(3):421-426.
58. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005;49(6):2289-2293.
59. Sacks LV, Pendle S, Orlovic D, Andre M, Popara M, Moore G, Thonell L, Hurwitz S. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin Infect Dis. 2001;32(1):44-49.
60. Conte JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyra-zinamide. Antimicrob Agents Chemother. 1999;43(6):1329-1333.
61. Conte JE, Golden JA, McQuitty M, Kipps J, Duncan S, McKenna E, Zurlinden E. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Che-mother. 2002;46(8):2358-2364.
62. Crofton J, Mitchison D. Streptomycin resistance in pulmonary tuberculosis. BMJ. 1948;2:1009-15.
63. Mitchinson DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005;171:699-706.
64. Wongsrichanalai C, Varma JK, Juliano JJ, Kimerling ME, MacArthur JR. Extensive drug resistance in malaria and tuberculosis. Emerg Infect Dis. 2010;16(7):1063-1067.
65. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, Drobniewski F, Gilpin C, Havelkova M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rusch-Gerdes S, Deun AV, Vincent V, Laserson K, Wells C, Cegielski JP. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380-387.
66. Centers for Disease Control and Prevention. Revised defnition of extensively drug-resistant tuberculosis. MMWR. 2006;55:1176.
67. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed. 2009;4:299-319.
68. Pandey R, Khuller GK. Nanotechnology based drug delivery system for the management of tuberculosis. Ind J Exper Biol. 2006;44:357-366.
69. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Ind J Chest Dis Allied Sci. 2006;48:171-176.
70. Hoet PH, Bruske-Hohlfeld I, Salata OV. Nanoparticles-known and unknown health risks. J Nano-biotechnol. 2004;2:12.
71. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Sys. 2002;19:425-498.
72. Venugopal J, Prabhakaran MP, Low S, Choon AT, Deepika G, Dev VR, Ramakrishna, S. Continuous nanostructures for the controlled release of drugs. Curr Pharm Des. 2009,15:1799-1808.
73. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263:797-800.
74. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long- circulating polymeric nanospheres. Science. 1994; 263:1600-1603.
75. Umamaheshwari RB, Jain NK. Receptor mediated targeting of lectin conjugated gliadin nanoparti-cles in the treatment of Helicobacter pylori. J Drug Target. 2003;11:415-423.
76. Cheng J, Teply BA, Sherif I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869-876.
77. Gu FX, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 2008;105:2586-2591.
78. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK. Poly (DL-lactide-co-glycolide) nanopar-ticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52:981-986.
79. Ahmad Z, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents. 2006;27:409-416.
80. Johnson CM, Pandey R, Sharma S, Khuller GK, Basaraba RJ, Orme IM, Lenaerts AJ. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49(10):4335-4338.
81. Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother. 2006;57(6):1146-1152.
82. Tripathi A, Gupta R, Saraf SA. PLGA nanoparticles of anti tubercular drug: drug loading and release studies of a water in-soluble drug. Int J PharmTech Res. 2010;2(3):2116-2123.
83. Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of nanoparticle encapsulated antituber-cular drugs. Drug Deliv. 2006;13:287-294.
84. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm. 2010;385:143-149.
85. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-gly-colide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents. 2004;24:599-604.
86. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis. 2003;83:373-378.
87. Ahmad Z, Pandey R, Sharma S, Khuller GK. Novel chemotherapy for tuberculosis: chemothera-peutic potential of econazole- and moxifoxacin-loaded PLG nanoparticles. Int J Antimicrob Agents. 2008;31:142-146.
88. Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother. 2004;54:266-268.
89. Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic- streptomycin evaluation in a murine tuberculosis model. Chemotherapy. 2007;53:437-441.
90. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54:761-766.
91. Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofoxacin-loaded polyisobutylcyanoacrylate nano-particles: pharmacokinetics and in vitro antimicrobial activity. Int J Pharm. 1998;168:255-259.
92. Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery- drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149-155.
93. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res. 1991;8:47-54.
94. Domb AJ. Liposphere parenteral delivery system. Proc Intern Symp Control Rel Bioact Mater. 1993;20:346-347.
95. Mullera RH, Maaenb S, Weyhersa H, Spechtb F, Lucksb JS. Cytotoxicity of magnetite-loaded polylac-tide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm. 1996;138:85-94.
96. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85:227-234.
97. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487-1490.
98. Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target. 2002;10:607-613.
99. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis. 2005;85:415-420.
100. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. Mannosylated nano-particulate carriers of rifabutin for alveolar targeting. J Drug Target. 2009;17(10):777-87.
101. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85:227-234.
102. Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery systems: desired feat for tuberculosis. J Adv Pharm Tech Res. 2010;1(2):145-163.
103. Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents. 2001;17:115-122.
104. Ain Q, Sharma S, Garg SK, Khuller GK. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm. 2002;239:37-46.
105. Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001;47:829-835.
106. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431-434.
107. Zhou H, Zhang Y, Biggs DL, Manning MC, Randolph TW, Christians U, Hybertson BM, Ng Ka-yun. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Contr Rel. 2005;107:288-299.
108. Ain Q, Sharma S, Khuller GK. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother. 2003;47(9):3005-3007.
109. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18(10):1405-1410.
110. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32:140-150.
111. Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lungs. Adv Drug Del Rev. 1990;5:149-161.
112. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res. 1991;8:1079-1086.
113. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm. 2004;269:37-49.
114. Agarwal A, Kandpal H, Gupta HP, Singh NB, Gupta CM. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother. 1994;38(3):588-593.
115. Gaspar MM, Cruz A, Penha AF, Reymao J, Sousa AC. Eleuterio CV, Domingues SA, Fraga AG, Filho AL, Cruz MEM, Pedrosa J. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents. 2008;31:37-45.
116. Chimote G, Banerjee R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J Biomed Mater Res B: Applied Biomaterials. 2010;94b(1):1-10.
117. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimi-crob Agents Chemother. 1997;41(6):1211-1214.
118. Furneri PM, Fresta M, Puglisi G, Tempera G. Ofoxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000;44(9):2458-2464.
119. Karki R, Subramanya G, Udupa N. Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids. Acta Pharmaceutica Sciencia. 2009;51:177-188.
120. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents. 2004;24:93-94.
121. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, El-Alim SA. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm. 2007;330:82-88.
122. Wiens T, Redelmeier T, Av-Gay Y. Development of a liposome formulation of ethambutol. Antimi-crob Agents Chemother. 2004;48(5):1887-1888.
123. Martin GP, Zeng XM, Marriott C. The controlled delivery of drugs to the lungs. Int J Pharm.1995;124:149-164.
124. Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother. 2004;53:635-640.
125. Barrow ELW, Winchester GA, Staas JK, Quenelle DC. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Che-mother. 1998;42(10):2682-2689.
126. Quenelle DC, Winchester GA, Staas JK, Barrow ELW, Barrow WW. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother. 2001;45(6):1637-1644.
127. Garcia-Contreras L, Sethuraman V, Kazantseva M, Godfrey V, Hickey AJ. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother. 2006;58:980-986.
128. Hasegawa T, Hirota K, Tomoda K, Ito F, Inagawa H, Kochi C, Soma G-I, Makino K, Terada H. Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent. Colloids and Surfaces B: Biointerfaces. 2007;60:221-228.
129. Samad A, Sultana Y, Khar RK, Chuttani K, Mishra AK. Gelatin microspheres of rifampicin cross-linked with sucrose using thermal gelation method for the treatment of tuberculosis. J Microen-capsulation. 2009;26(1):83-89.
130. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315-1319.
131. Zhang W, Jiang X, Hu J, Fu C. Rifampicin polylactic acid microspheres for lung targeting. J Micro-encapsulation. 2000;17(6):785-788.
132. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
133. Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsulation. 1995;12(4):401-407.
134. Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Ind J Pharm Sci. 2006;68(5):575-578.
135. Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Fazeli MR, Jamalifar H. Formulation and in vitro evaluation of ciprofoxacin containing niosomes for pulmonary delivery. J Microencapsulation. 2010;27(7):618-627.
136. Tomalia DA, Naylor AM, Goddar WA. Starburst dendrimers: control of size, shape, surface, chemistry, and topology. Angew Chem. 1990;102:119-157.
137. Tomalia DA, Durst HD. Supramolecular chemistry-directed synthesis and molecular recognition. Top Curr Chem. 1993;165:193-313.
138. Frechet JMJ. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. Science.1994;263:1710-1715.
139. Voit BI. Dendritic polymers: from aesthetic macromolecules to commercially interesting materials. Acta Polym. 1995;46(2):87-99.
140. De Brabender-Van Den Berg EMM, Meijer EW. Poly(propylene imine) dendrimers: large scale synthesis by heterogeneously catalyzed hydrogenation. Angew Chem Int Ed Engl. 1993;32(a):1308-1311.
141. Pricl S, Fermeglia M. Molecular simulations of host-guest inclusion compounds: an approach to the lactodendrimers case. Carbohydrate Polymers. 2001;45:23-33.
142. Roberts JC, Bhalbat MK, Zera RTJ. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. Biomed Mater Res. 1996;30:53-65.
143. Kumar PV, Agashe H, Dutta T, Jain NK. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Current Drug Deliv. 2007;4:11-19.
144. Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded man-nosylated dendrimers. J Drug Target. 2006;14(8):546-556.
145. Frijlink HW, Boer AD. Dry powder inhalers for pulmonary drug delivery. Expert Opinion Drug Deliv. 2004;1(1):67-86.
146. Maa YF, Prestrelski SJ. Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotech. 2000;1(283-302):1389-2010.
147. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Che-mother. 2009;53(4):1338-1343.
148. Sawatdee S, Worakul N, Srichana T. Preparation of isoniazid as dry powder formulations for inhalation by physical mixing and spray drying. Malays J Pharm Sci. 2006;4(1):43-63.
149. Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, VerBerkmoes JL, Elbert KJ, Hickey AJ, Edwards DA. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010;54(4):1436-1442.
150. Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, Edwards D. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008;25(4):805-811.
151. Constantinides PP, Chaubal M V, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev. 2008;60:757-767.
152. ®), as a parenteral drug carrier for passive drug targeting. Int J Pharm. 2004;273:75-83.
153. Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nano-emulsion of primaquine. Int J Pharm. 2008;347:136-143.
154. Ahmed M, Ramadan W, Rambhu D, Shakeel F. Potential of nanoemulsions for intravenous delivery of rifampicin. Pharmazie. 2008;63:806-811.
155. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785-796.
156. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Muller RH, Ehlers S. Preparation of a clo-fazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45:77-83.
157. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A small molecule nitroi-midazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405:962-966.
158. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. Preclinical testing of the nitroimidazopyran PA-824 for activity against My-cobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005;49:2294-2301.
159. Matsumoto M, Hashizume H, Tomoshige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Plos Med. 2006;3:466.
160. Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo [2,1-b] oxazoles. J Med Chem. 2006;49:7854-7860.
161. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmer-man P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227.
162. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother. 2009;53:3989-3991.
163. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifoxacin, ofoxacin, sparfoxacin, and ciprofoxacin against Mycobac-terium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo effcacy. Antimicrob Agents Chemother. 2007;51:576-582.
164. Yoshimatsu TE, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifoxation in murine tuberculosis. Antimicrob Agents Chemother. 2002;46:1875-1879.
165. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. Bactericidal action of gatifoxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacte-rium tuberculosis. Antimicrob Agents Chemother. 2005;49:627-631.
166. Shindikar AV, Viswanathan CL. Novel fuoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett. 2005;15:1803-1806.
167. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol. 2005;144:80-87.
168. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. Identifcation of a new antitubercular drug candidate, SQ109, from a corabinatorial library of 1,2-et-hylenediamines. J Antimicrob Chemother. 2005;56:968-974.
169. Arora S. Eradication of Mycobacterium tuberculosis infection in 2 months with LL3858: a preclini-cal study. Int J Tuber Lung Dis. 2004;8(Suppl.1):S29.
170. Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis. Med Chem. 2007;3:301-316.
171. Alcala L, Ruiz-Serrano MJ, Peres-Fernandez Turegano C, Carcia De Viedma D, Diaz-Infantes M, Marin-Arriaza M, Bouza E. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to frst-line antituberculous drugs. Antimicrob Agents Che-mother. 2003;47:416-417.
172. Fortun J, Martin-Davila P, Navas E, Peres-Elias MJ, Cobo J, Tato M, de la Pedrosa EG, Gomez-Mam-paso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Che-mother. 2005;56:180-185.